Cannabis derived from hemp – specifically THCAnd CBN, And Convention on Biological Diversity First demonstrated anti-cancer activity in mice nearly 50 years ago.1 Since then, several researchers have investigated the ability of endogenous, plant-derived, and synthetic cannabinoids to cause cancer cell death. in the laboratory (outside a living organism) and inhibit tumor growth in animals.
However, largely because of the federal ban on cannabis, promising research into the anti-cancer effect of cannabis — backed by anecdotal accounts of cancer remission induced by cannabis oil extracts — has yet to translate into clinical trials. Much work remains to be done to demonstrate that cannabis and cannabis can fight cancer in humans, including as an adjunct to other treatments such as chemotherapy and radiation, and to incorporate their use into treatment protocols.
With 1.9 million Americans diagnosed with cancer each year, this stark disconnect between the lab and the clinic is another troubling byproduct of the war on drugs. While it is true that cannabis has been widely accepted for its ability to treat cancer symptoms and the side effects of chemotherapy, drastic changes to the research landscape are unlikely until the plant is canceled/rescheduled at the federal level. In the meantime, preclinical work continues. Here are five other research papers published in recent weeks, with generally encouraging results.
Convention on Biological Diversity Lung cancer stem cells
cannabidiol (Convention on Biological Diversity) It has previously been proven to be able to fight several different types of cancer cells, but its effect on cancer stem cells2 A small subpopulation of self-renewing cells that drive tumor initiation and progression is not well known. A couple of Danish researchers sought to find out more. In a paper published in the magazine pharmaceutical3 In November 2021, they described a study in which they tested Convention on Biological DiversityIts effect on cancer stem cells and cancer cells that are difficult to treat. “We found that Convention on Biological Diversity It reduces viability and cell death occurs in both groups of cells “in a dose-dependent manner,” the authors wrote. “However, the precise mechanisms Convention on Biological Diversity in CSCs remains to be elucidated and appears to depend on the cell context.”
Convention on Biological Diversity Combined with chemotherapy
Three researchers from the Canadian Ontario Veterinary College conducted a study on Convention on Biological DiversityPotential to treat urothelial carcinoma in dogs, the most common form of bladder cancer in dogs, either alone or in combination with chemotherapy in the laboratory. In veterinary practice, treatment with chemotherapy alone causes most dogs to become ill within a year, the authors wrote. In their study, the results of which were published in the journal Plus One4And Convention on Biological Diversity It reduced cell vitality and led to cell death in dogs’ urothelial cells on its own – and it worked best when paired with chemotherapy. “Other studies in vivo Justified, clinical trials are necessary to investigate how best to implement it Convention on Biological Diversity— combination therapies of chemotherapy in a clinical setting,” the authors concluded — in a familiar phrase that could also apply to human cancers.
Cannabis to treat neuropathy caused by chemotherapy
Peripheral neuropathy is a side effect of chemotherapy drugs that affects approximately 70 percent of patients within the first month of treatment. It results from nerve damage and appears in the form of weakness, numbness and pain in the hands and feet. According to a group of authors at Mayo Clinic in Minnesota and Sutter Health in California in November 2021 integrative cancer therapy paper5, topical creams containing THC Wow Convention on Biological Diversity It can help patients with this condition. Their paper reviews the cases of 26 cancer patients who have tried topical cannabis to treat the condition, and 22 of them report finding relief. These data “provide a rationale for initiating a randomized, placebo-controlled trial using a standard product to determine the actual efficacy of such treatment,” the authors wrote.
Two weeks later, another paper was published in the journal Neurotherapy6 Pointed out that the management of synthetic analog of Convention on Biological Diversity the name of the thing pix-101 in combination with the chemotherapy drug paclitaxel provides long-lasting relief from mechanical and cold pain (a model of neuropathic pain) in mice. Further analysis by researchers based in Brazil suggested that this effect was mediated by PPARNuclear receptors, a known target of Convention on Biological Diversity.
Cannabis for cachexia linked to cancer
in a review in Journal of Cachexia, Sarcopenia and Muscle7In this study, a group of researchers from University College London evaluated the potential of cannabis to treat cancer-related cachexia, a condition characterized by involuntary weight loss and loss of appetite. Previous studies support the use of cannabis for cachexia in other chronic diseases including Immunity deficiency Virus and multiple sclerosis,” the authors wrote – but there is a lack of data on this intervention in cancer cohorts. The literature search showed ten studies: four randomized controlled trials and six non-randomized studies. Meta-analyses of these limited studies revealed no statistically significant benefits of using cannabis, but patient-reported anecdotal observations from non-randomized studies indicated an improvement in appetite.
Inhibition of endocannabinoid degrading enzymes
If preclinical research shows that cannabinoids can inhibit cancer cell proliferation, tumor invasion and metastasis (the spread of cancerous tumors to new sites), and support cancer cell death and degradation, then approaches aimed at boosting levels of its own cannabinoids, or endocannabinoids, could work. Also as an anti-cancer treatment? This is the primary question explored in a recent journal review article crabs8. The authors based in Germany suggest: “In addition to direct activation of cannabinoid receptors by exogenous application of corresponding stimuli, another strategy is to activate these receptors by increasing endocannabinoid levels in the corresponding pathological hotspots.” They set out to review the results of previous studies showing that inhibition of enzymes FAAH And Majel, which degrades the THC– such as the endocannabinoids anandamide and 2-AG, with a decrease in tumor development and spread. Modulation of enzymatic activity to improve endocannabinoid tone has been the subject of ongoing interest for a variety of therapeutic outcomes, but little progress has been made regarding clinical advances.
Nate Seltenrich, a freelance science journalist based in the San Francisco Bay Area, covers a wide range of topics including environmental health, neuroscience, and pharmacology. Copyright, Project Convention on Biological Diversity. It may not be reprinted without So.